Immuno-Diagnostic Interest in Monitoring CD16+CD56+ (Natural Killer) Cells and CD19+CD45+ (B Lymphocytes) in Individuals Newly Diagnosed with HIV in a Tertiary Care Center.
Jamil A Al-MughalesPublished in: Journal of clinical medicine (2024)
Findings advocate for the usefulness of CD16+CD56+ and CD19+CD45+ phenotyping in characterizing the severity of HIV infection and its impact on both the humoral and cellular immunity, as well as monitoring the effectiveness of treatment.
Keyphrases
- natural killer cells
- antiretroviral therapy
- newly diagnosed
- tertiary care
- hiv infected
- hiv positive
- immune response
- human immunodeficiency virus
- randomized controlled trial
- systematic review
- hiv aids
- hiv testing
- high throughput
- peripheral blood
- men who have sex with men
- combination therapy
- south africa
- replacement therapy